IMG_5452-Small.png
 

ABOUT US

The Global CKD and Hypertension Pandemic affects 1.13 Billion people worldwide, inflicting death and suffering. 
Global healthcare costs are estimated at over $500 Billion (1) a year.

Hypertension is one of the main causes of CKD - costing Medicare, in the USA alone,
over $84 billion (2,3) a year.

The only current solution, Dialysis, dramatically reduces patients' quality-of-life

 – 5-year patient survival probability for all renal replacement therapy - 50.8% (4).

 

CureSpec was Founded in 2020, a wholly owned subsidiary of Medispec.
Our first market-ready product, Nephrospec™, is intended for the interrelated treatment of: 

-       CKD (Chronic Kidney Disease)

-       Hypertension (High Blood Pressure)

NephroSpec - Saving lives & costs

NephroSpec promotes new blood vessel formation and restores damaged tissue function by means of its patented ShockWave technology. 

We hold an Established, market-ready product, with a strong IP portfolio, which includes a granted U.S. patent, a fully developed CE-Marked device & Promising preliminary clinical results.

 

CureSpec has an established Production facility, a Global distribution chain and an experienced management team. 

  1. https://www.cdc.gov/chronicdisease/programs-impact/pop/high-blood-pressure.htm

  2. https://www.cdc.gov/kidneydisease/basics.html

  3. Gaziano TA, Asaf B, S Anand, et.al. The global cost of non-optimal blood pressure. J  Hypertens. 2009

  4. Kramer A, Boenink R, Noordzij M, et al. The ERA-EDTA Registry Annual Report 2017 : a summary. 2020

 

OUR PRODUCT

TM

TM

TM

TM

NephroSpec    - a medical device manufactured by CureSpec.

NephroSpec    - a safe, non-invasive shockwave device intended for the treatment of CKD and Hypertension

NephroSpec    - promotes new blood vessel formation and restores damaged tissue function through its patented technology

NephroSpec    - saves up to 80% of costs while easing suffering and needless loss of lives

Benefits include:

  • Complementary solution to optimal medical care for CKD and hypertension

  • Kidney function improvement in weeks

  • Outpatient treatment delays onset of dialysis

ARAS Kidney
pre

Pre treatment

post

Post Shockwave treatment

CureSpec uses shockwave technology to produce a neovascularization affect on the kidneys.

 
 

Our Team

Avner Spector

Founder,
Active Chairman

Mr. Spector has over 30 years experience in the international Medtech industry, having held top R&D management positions in medical instrument companies in Israel and the US. He holds a B.Sc. Degree in Mechanical Engineering from Ben-Gurion-University of the Negev, Israel.

  • Grey LinkedIn Icon

Rotem Kaynan

CEO

Mr. Kaynan is a Biomedical Engineer, 2005 Technion – Israel Institute of Technology. 

More than 15 years of experience in Medical Devices,clinical applications, sales and product management

  • Grey LinkedIn Icon

Ophir Brandt

CFO

Mr. Brandt is a Certified Public Accountant (CPA) from the Bar-Ilan University, and holds an MBA degree from the Hebrew University. Mr. Brandt has over 10 years of experience in financial management, including as a CFO in the private sector and as a Senior Auditor at Ernst & Young (EY). Mr. Brandt joined Medispec in 2018.

  • Grey LinkedIn Icon

Alex Slutzker

VP Clinical, Cofounder

Dr. Slutzker (Ph.D) has 10 years of experience in the clinical diagnostics and medical device fields. He holds a doctorate in the fields of Molecular biology, biochemistry and microbiology from the Ben-Gurion-University of the Negev, Israel

  • Grey LinkedIn Icon

Hagay Spector

R&D Director

Mr. Spector is an Electronics Engineer, (from 2009, HIT- Holon Institute of Technology). His major expertise is Product Development in all of its layers with wide knowledge in Shockwave systems and X-ray Vision. Hagay joined Medispec in 2009 and became the CTO  in 2017.

  • Grey LinkedIn Icon

Advisory Board

Lilach O. Lerman, MD, PhD

The Arthur M. and Gladys D. Gray Professor in Honor of Dr. Howard A. Andersen

Professor of Medicine and Physiology

Director, Reno-Vascular Research Laboratory

Division of Nephrology and Hypertension

Mayo Clinic

  • Grey LinkedIn Icon

Amir Lerman, M.D.

Barbara Woodward Lips Professor 

Associate Chair, Cardiovascular  Medicine

Director - Cardiovascular Research Center

Consultant, Department of Cardiovascular Medicine

Mayo Clinic

  • Grey LinkedIn Icon
 

Contact Us

Our Address

40 Hataasiya St.  Yehud

P.o Box 292, 5610103 , israel

Thanks for submitting!